

World Conference On Genitourinary Cancers 2025

Financial Disclosures

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified financial relationships are thoroughly mitigated according to PIM policy. PIM is committed to providing its learners with high-quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity. These relationships have been mitigated to:

Michael Abern reports being an employee/owner at Droplet Biosciences and Medtronic. Michael Abern reports receiving grant/research support from Droplet Biosciences and Medtronic. Michael Abern reports serving as a consultant/advisory board member for Droplet Biosciences and Medtronic.

Daniel Barocas reports receiving grant/research support from NIH, AHRQ, and Movember Foundation. Daniel Barocas reports serving as a consultant/advisory board member for Pacific Edge, Lantheus, Lynx Dx, and Astellas/Pfizer.

Katy Beckermann reports receiving grant/research support from BMS-IASLC-LCFA, Pionyr, and Aravive. Katy Beckermann reports serving as a consultant/advisory board member for Arcus, Adicet, Aravive, Aveo, BMS, Exelixis, Merck, Eisai, Nimbus, and Xencor.

Stephanie Berg reports serving as a consultant/advisory board member for Exelixis, Eisai, Natera, Guardant, Xencor; Consultant: Aptitude Health, Curio Science, Targeted Oncology, and Cardinal health.

Mehmet Bilen reports receiving grant/research support from Merck, Xencor, Bayer, Bristol-Myers Squibb, Genentech/Roche, SeaGen, Incyte, Nektar, AstraZeneca, Tricon Pharmaceuticals, Genome & Company, AAA, Peloton Therapeutics, and Pfizer. Mehmet Bilen reports serving as a consultant/advisory board member for Exelixis, Bayer, BMS, Eisai, Pfizer, AstraZeneca, Janssen, Calithera Biosciences, Genomic Health, Nektar, EMD Serono, SeaGen, and Sanofi.

David Braun reports receiving grant/research support from NIH/NCI, DOD, CRI, and AstraZeneca. David Braun reports serving as a consultant/advisory board member for

Accolade 2nd MD, DLA Piper, Dechert, Compugen, Link Cell Therapies, Scholar Rock, NeoMorph, Nimbus, Exelixis, AVEO, Eisai, Daiichi Sankyo, and Elephas. David Braun reports the following non-mutual funds stock ownership/stock options: Elephas.

Jacqueline Brown reports receiving grant/research support from Medicenna, Merck, Duality Biologics, Pliant Therapeutics, Astellas, MacroGenics, Xencor, Surface Oncology, and Adcentrx. Jacqueline Brown reports serving as a consultant/advisory board member for Pfizer, EMD Serono, Xencor, Exelixis, Gilead, and AstraZeneca.

Manojkumar Bupathi reports being an employee/owner at Manojkumar Bupathi. Manojkumar Bupathi reports serving as a consultant/advisory board member for Merck, Pfizer, J&J, Agendia, Fencer, SeaGen, and AstraZeneca.

Robert Califf reports serving as a consultant/advisory board member for Population Health Partners and American Health Association.

Sam Chang reports serving as a consultant/advisory board member for EnGene, Vesica Health, Astellas Pharma US, Inc., Folde, Johnson & Johnson, Lantheus, Merck & Co., Inc., Nonagen, Pacific Edge, Pfizer Inc., Photocure Inc., Prokarium, Tu Therapeutics, Urogen Inc., Valar Labs, ImmunityBio Inc, Janssen Pharmaceutica Products, LP, CG Oncology, and Lantheus.

Robert Dreicer reports receiving grant/research support from Arvinas, Regeneron, Seagen, and BMS. Robert Dreicer reports serving as a consultant/advisory board member for Urogen, Pfizer, Astellas, Bayer, Merck, and LNC Pharma.

Jason Efstathiou reports receiving grant/research support from Blue Earth Diagnostics. Jason Efstathiou reports serving as a consultant/advisory board member for Blue Earth Diagnostics, Boston Scientific, MDxHealth, AstraZeneca, Lantheus, IBA, Astellas/Pfizer, Elekta, Clarity Pharmaceuticals, Angiodynamics, Janssen/Johnson&Johnson, and Bioprotect.

Darren Feldman reports receiving grant/research support from Exelixis, Telix, and BMS. Darren Feldman reports serving as a consultant/advisory board member for Exelixis, Debiopharm, Xencor, Renibus, Telix, and BioNTech. Darren Feldman reports Patent Holder/Royalties from UpToDate.

Mark Fleming reports serving on a speakers bureau/honoraria for Novartis.

Benjamin Garmezy reports being an employee/owner at Sarah Cannon Research Institute. Benjamin Garmezy reports receiving grant/research support from Abbvie, Accutar Biotechnology, Arcus Biosciences, Arvinas, AstraZeneca, AVEO Oncology, CRISPR Therapeutics, Eikon Therapeutics, Exelixis, Roche/Genentech, Flare Therapeutics, Harbour

BioMed, IDEAYA Biosciences, Janssen, Janux Therapeutics, Jubilant Therapeutics, Kineta, Kinnate BioPharma, Loxo, Mink Therapeutics, Nuvation Bio, Profound Bio, Takeda Theapeutics, Teon Therapeutics, Tmunity Therapeutics, Xencor, and Zenshine. Benjamin Garmez reports serving as a consultant/advisory board member for Abbvie, Adaptimmune, Adicent Therapeutics, AIQ Global, Amgen, Arcus Biosciences, Arvinas, AstraZeneca, AVEO Oncology, Bayer, Bicycle Tx, Eisai, EMD Serono, Exelixis, Janssen, Merck, Novartis, Pfizer, Rondo Therapeutics, Sanofi-Aventis, Seagen, and Xencor.

Daniel George reports receiving grant/research support from Astellas [Prostate cancer]; AstraZeneca [prostate cancer]; Bristol Myers Squibb [Renal cell carcinoma]; CORVUS [renal cell carcinoma]; Exelixis [renal cell carcinoma]; Janssen [Prostate cancer]; Novartis [prostate cancer]; Pfizer [Renal cell carcinoma]; Merck Sharp & Dohme [renal cell carcinoma]. Daniel George reports serving on a speakers bureau/honoraria for American Association for Cancer Research [Senior editor]; Bayer [Honorarium, travel accommodations – Prostate cancer]; Exelixis [Honorarium, travel accommodations – Prostate cancer]; Medscape Education [prostate cancer]; Millennium Medical publishing, Clinical Advances in Hematology & Oncology [Co-editor-in-chief]; MJH Life Sciences [Honorarium – Prostate cancer]; Pfizer [Honorarium – Renal cell carcinoma, prostate cancer]; UroGPO [Honorarium]; UroToday (Digital Science Press) [Honorarium,]; IdeoLog Health[Prostate, bladder, renal cell cancer] WebMD [Renal cell cancer]. Daniel George reports serving as a consultant/advisory board member for ABRX [Prostate Cancer]; Astellas [Prostate cancer]; AstraZeneca [Prostate cancer]; Bayer [Prostate cancer]; Eisai [renal cell carcinoma]; Exelixis [Prostate cancer, renal cell carcinoma]; Janssen Pharmaceuticals [prostate cancer, bladder cancer]; Merck Sharp & Dohme [Renal cell cancer, bladder cancer]; MJH Life Sciences [cancer]; Pfizer [Prostate cancer, renal cell carcinoma]; Sumitovant Biopharma [prostate cancer]; Novartis [prostate cancer].

Rajan Gupta reports serving on a speakers bureau/honoraria for Bayer Pharma AG. Rajan Gupta reports serving as a consultant/advisory board member for Bayer Pharma AG, Bracco Diagnostics, Bard, Philips, and Quibim.

Naomi Haas reports serving as a consultant/advisory board member for Eisai.

Hans Hammers reports receiving grant/research support from BMS, Merck, Abbvie, Nikang, HiberCell, and Werewolf Therapeutics. Hans Hammers reports serving on a speakers bureau/honoraria for MJH and Onclive. Hans Hammers reports serving as a consultant/advisory board member for Eisai, Merck, Eli Lilly, Corvus, Surface Oncology, Aveo, J&J, and Scholar Rock.

Michael Harrison reports receiving grant/research support from Astellas, Bayer, Exelixis, Pfizer, BMS, Johnson & Johnson, Abbvie, and Merck. Michael Harrison reports serving as a consultant/advisory board member for Eisai, Exelixis, Telix, and Johnson & Johnson.

Elisabeth Heath reports serving on a speakers bureau/honoraria for Astellas, Astra Zeneca, Sanofi, and Bayer. Elisabeth Heath reports serving as a consultant/advisory board member for Sanofi.

Jean Hoffman-Censits reports receiving grant/research support from Genentech. Jean Hoffman-Censits reports serving as a consultant/advisory board member for Gilead Pharmaceuticals and Pfizer. Jean Hoffman-Censits reports receiving other financial or material support from Seattle Genetics, Pfizer, Astellas, EMD Serono, Ikena Oncology, Daiichi, and LOXO.

Karen Hoffman reports being an employee/owner at The University of Texas MD Anderson Cancer Center. Karen Hoffman reports receiving grant/research support from Johnson & Johnson and Medical Systems. Karen Hoffman reports serving as a consultant/advisory board member for MDX Health.

Jiaoti Huang reports serving as a consultant/advisory board member for Artera, Kingmed Diagnostics, MoreHealth, OptraScan, York Biotechnology, Chimigen Bio, Pfizer and Sisu Pharma. Jiaoti Huang David Braun: Artera, Kingmed Diagnostics, MoreHealth, OptraScan, York Biotechnology, Chimigen Bio, and Sisu Pharma.

Heather Jacene reports receiving grant/research support from Blue Earth Diagnostics and Lantheus. Heather Jacene reports serving on a speakers bureau/honoraria for Medscape. Heather Jacene reports serving as a consultant/advisory board member for Luminance Biosciences. Heather Jacene reports Patent Holder/Royalties from Cambridge Publishing.

Eric Jonasch reports receiving grant/research support from Abbvie, Aveo, BMS, Corvus, Merck, NiKang, ProFoundBio, and Telix. Eric Jonasch reports serving as a consultant/advisory board member for Arcus, Aveo, Eisai, Exelixis, Ipsen, Merck, Novartis, NiKang, and Takeda.

Monika Joshi reports being an employee/owner at Penn State Cancer Institute. Monika Joshi reports receiving grant/research support from AstraZeneca. Monika Joshi reports serving as a consultant/advisory board member for Eisai, Gilead Sciences, and Seagen. Monika Joshi reports receiving other financial or material support from Dava Oncology-Travel and Stay ; Caris LifeSciences- Travel and stay for lab tour; Curio Sciences- Co-Moderate the Opinions in the Evolving Landscape in Advanced Urothelial Carcinoma: An Interactive Local Workshop.

Elizabeth Kessler reports receiving grant/research support from Astellas Pharma US, Inc. Bristol Myers Squibb, Pfizer Inc., Merck & Co., Inc., and Eli Lilly and Company.

Michael Lattanzi reports serving on a speakers bureau/honoraria for Astellas, Aveo, Exelixis, Merck, and Pfizer. Michael Lattanzi reports serving as a consultant/advisory board member for Astellas, Aveo, Exelixis, Merck, and Pfizer.

Jonathan Leeman reports receiving grant/research support from Varian, NH Theraguix, and ViewRay. Jonathan Leeman reports serving as a consultant/advisory board member for ViewRay Systems.

Stacy Loeb reports receiving grant/research support from Endo Pharmaceuticals. Stacy Loeb reports serving as a consultant/advisory board member for Endo Pharmaceuticals, Blue Earth, Doceree, Astellas, and Savor Health.

Benjamin Maughan reports serving as a consultant/advisory board member for Telix, Janssen, Sanofi, Curio, Xencor, Bayer, Binaytara, NCCN, MashUpMedia, DAVA Oncology, INternational Drug Development Co, Eisai, RCC CDRMP, OncLive, Pfizer, Arcus, and MATOs.

Matthew Milowsky reports receiving grant/research support from Merck, Bristol-Myers Squibb, Alliance for Clinical Trials in Oncology, ALX Oncology, Novartis, Acrivon Therapeutics, PCCTC, OncoC4, Flare Therapeutics, Loxo/Lilly, Astellas Pharma, Pfizer, Amgen, Roche, and G1 Therapeutics. Matthew Milowsky reports the following non-mutual funds stock ownership/stock options: Pfizer and Gilead. Matthew Milowsky reports other financial or material support from G1 Therapeutics.

Alicia Morgans reports receiving grant/research support from Astellas, Bayer, Pfizer, Sumitomo Pharma, Inc, and Johnson and Johnson. Alicia Morgans reports serving as a consultant/advisory board member for Astellas, AstraZeneca, Bayer, BMS, Curium, Lantheus, Johnson and Johnson, Merck, Macrogenics, Novartis, Pfizer, Sumitomo Pharma, Inc, Telix, Tomar, and Quest Diagnostics.

Kelvin Moses reports serving as a consultant/advisory board member for Boston Scientific.

Chandler Park reports being an employee/owner at Norton Cancer Institute. Chandler Park reports receiving grant/research support from Astellas Pharma, AstraZeneca, Bayer, BioClinica, Bristol-Myers Squibb, Exelixis, Genentech, Gilead Sciences, Janssen, Biotech, Merck, Roche, and Pfizer. Chandler Park reports serving on a speakers bureau/honoraria for Astellas, AstraZeneca, Caris, Eisai, Gilead, Janssen, Merck, and Pfizer. Chandler Park reports serving as a consultant/advisory board member for Astellas Pharma, AstraZeneca, Aveo, Bristol-Myers Squibb, CARIS, Eisai, Janssen, Biotech, Merck, and Pfizer. Chandler

Park reports receiving other financial or material support from OncLive, Targeted Oncology, Dava, MEC, Ideology, GU oncology now.

John Phillips reports being an employee/owner at Tennessee Oncology.

Phillip Pierorazio reports receiving grant/research support from Ferring (LUNAR Trial) Site PI. Phillip Pierorazio reports serving as a consultant/advisory board member for Johnson and Johnson and Photocure. Phillip Pierorazio reports Patent Holder/Royalties from Wolters Kluwer (UpToDate Chapter).

Elizabeth Plimack reports receiving grant/research support from Merck, BMS, and Pfizer. Elizabeth Plimack reports serving as a consultant/advisory board member for AbbVie, AstraZeneca, BMS, Eisai, EMD Serono, Flatiron, Astellas, Merck, Pfizer, SeaGen, Signatera, SyntheKine, Aura Biosciences, Adaptimmune, 23andMe, Daiichi Sankyo, and UroGen.

Mark Pomerantz reports being an employee/owner at Dana-Farber Cancer Institute. Mark Pomerantz reports receiving grant/research support from Prostate Cancer Foundation and NIH.

Edwin Posadas reports serving on a speakers bureau/honoraria for Bayer. Edwin Posadas Rettig reports serving as a consultant/advisory board member for Bayer and Daiichi-Sankyo.

Lisa Raff reports being an employee/owner at OneOncology. Lisa Raff reports serving on a speakers bureau/honoraria for Nuvation Bio, Pfizer, J&J, and AstraZeneca. Lisa Raff reports serving as a consultant/advisory board member for Pfizer.

Matthew Rettig reports receiving grant/research support from Merck, Novartis, Pfizer, Lantheus, and Immune Bio. Matthew Rettig reports serving on a speakers bureau/honoraria for Bayer and Johnson & Johnson. Matthew Rettig reports serving as a consultant/advisory board member for AVEO and Bayer.

Brian Rini reports receiving grant/research support from AVEO, Arcus, Merck, HiberCell, Incyte, Janssen, Adela, Astra-Zeneca, Tempus, Gilead, POINT Biopharma, BMS, Pfizer, Daiichi Sankyo, Genentech, Exelixis, and Surface Oncology. Brian Rini reports serving as a consultant/advisory board member for Eisai, BMS, Pfizer, Astra-Zeneca, Aveo, Merck, Debiopharm, Exelixis, MashupMD, Xencor, and JNJ.

Ashley Ross reports receiving grant/research support from Blue Earth, Bayer, Boston Scientific, Sumitomo, and Pfizer. Ashley Ross reports serving on a speakers bureau/honoraria for Blue Earth, Veracyte, Janssen, and Lantheus. Ashley Ross reports serving as a consultant/advisory board member for Bayer, Astellas, Pfizer, Lantheus, Blue Earth, Veracyte, and BillionToOne.

Charles Ryan reports serving as a consultant/advisory board member for Bayer, Oric, Pfizer, Novartis, and Tolmar. Charles Ryan reports receiving other financial or material support from Lilly.

Mutlay Sayan reports being an employee/owner at Dana-Farber Cancer Institute and Brigham and Women's Hospital.

Kristen Scarpato reports receiving grant/research support from CxBladder. Kristen Scarpato reports serving as a consultant/advisory board member for Urogen and Photocure.

Kerry Schaffer reports receiving grant/research support from Tempus. Kerry Schaffer reports serving on a speakers bureau/honoraria for DAVA. Kerry Schaffer reports serving as a consultant/advisory board member for Bayer, Sanofi, MashupMedia, Janssen, and MJH Events.

Michael Schweizer reports receiving grant/research support from Novartis, Zenith, Epigenetics, BMS, Merck, Epigenetix, Xencor, Ambrx, Oric Pharmaceuticals, AstraZeneca, Janssen, and Pfizer. Michael Schweizer reports serving as a consultant/advisory board member for Fibrogen, Daiichi Sankyo, Janssen, and Pfizer.

Eric Shinohara reports receiving grant/research support from CAUSAL: Cohort to Augment the Understanding, NIH 4UH3CA260318-03 of Sarcoma Survivorship Across the Lifespan. Eric Shinohara reports serving on a speakers bureau/honoraria for ZERO prostate cancer support group. Eric Shinohara reports serving as a consultant/advisory board member for ZERO Medical Advisory Board.

Brian Shuch reports serving on a speakers bureau/honoraria for Merck and Telix. Brian Shuch reports serving as a consultant/advisory board member for Telix, Merck, and Veracyte. Brian Shuch reports Patent Holder/Royalties from UpToDate.

Arlene Siefker-Radtke reports receiving grant/research support from Bicycle Therapeutics, Bristol Myers Squibb, Jannssen, Loxo and Merck. Arlene Siefker-Radtke reports serving as a consultant/advisory board member for Abbvie, Astellas, Biccyle Therapeutics, Biohaven, EMD Serono, G1 Therapeutics, Gilead, Immunomedics, Janssen, Loxo, Merck, Pfizer, Seattle Genetics and Taiho.

Bradley Somer reports receiving grant/research support from AstraZeneca, Genentech, Guardant, Merck, Amgen, Pfizer, Astellas, and Daiichi Sankyo. Bradley Somer reports serving on a speakers bureau/honoraria for Merck, AstraZeneca, and Amgen. Bradley Somer reports serving as a consultant/advisory board member for Bayer, Pfizer, and Amgen.

Alan Tan reports receiving grant/research support from Regeneron and Exelixis. Alan Tan reports serving on a speakers bureau/honoraria for Pfizer, Astellas, Exelixis, BMS, Merck, and Aveo. Alan Tan reports serving as a consultant/advisory board member for Johnson and Johnson and Exelixis. Alan Tan reports the following non-mutual funds stock ownership/stock options: Personalis, Intellia, Crisper, Nektar, and Bluebird.

Karine Tawagi reports serving on a speakers bureau/honoraria for AstraZeneca. Karine Tawagi reports serving as a consultant/advisory board member for Seagen and Astellas.

Ulka Vaishampayan reports receiving grant/research support from BMS and Merck Inc. Ulka Vaishampayan reports serving on a speakers bureau/honoraria for Bayer and Exelixis. Ulka Vaishampayan reports serving as a consultant/advisory board member for BMS, Bayer, Exelixis, Novartis, Pfizer, Astra Zeneca, Zenmab, Astellas, Mural, and Gilead.

Elizabeth Wulff-Burchfield reports receiving grant/research support from Pfizer Global Medical Grants, and Acer Therapeutics. Elizabeth Wulff-Burchfield reports serving on a speakers bureau/honoraria for Exelixis, Targeted Oncology, and Curio Science. Elizabeth Wulff-Burchfield reports serving as a consultant/advisory board member for Astellas, Aveo Oncology, Bristol Myers Squibb, Exelixis, Johnson and Johnson, Bayer, EMD Serono, and Pfizer. Elizabeth Wulff-Burchfield reports the following non-mutual funds stock ownership/stock options: Immunomedics and Nektar. Elizabeth Wulff-Burchfield reports other financial or material support from AstraZeneca.

Jeff Yorio reports being an employee/owner at Texas Oncology. Jeff Yorio reports serving on a speakers bureau/honoraria for IDEOlogy Health and Castle Biosciences. Jeff Yorio reports serving as a consultant/advisory board member for Merck and Replimmune.